Is stem cell therapy for Premature Ovarian Insufficiency worth it?
Current evidence does not support buying cell therapy as a tissue-regenerative alternative to hormone therapy, donor-oocyte IVF or other established POI care. The most defensible access is through a well-designed registered clinical trial with independent oversight, transparent costs and no promise of ovarian restoration, pregnancy or live birth. Specialist counselling should cover hormone health, fertility options and psychological support.
How stem cells are studied for Premature Ovarian Insufficiency
Premature ovarian insufficiency (POI) is loss of ovarian function before age 40, confirmed through menstrual history and biochemical assessment. It can affect fertility, bone, cardiovascular, sexual and psychological health. Causes and residual ovarian activity vary. Mesenchymal stromal cells (MSCs) and other biological approaches are being studied, but proposed follicle, hormonal or immune mechanisms have not established restored fertility or live birth. Cell injection or infusion is not standard POI care. The registry table on this page lists relevant studies and their current recruitment status.
Am I a candidate? → · Premature Ovarian Insufficiency: full overview → · Premature Ovarian Insufficiency cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Premature Ovarian Insufficiency: cell-therapy evidence and registered trials
- How much does stem cell therapy for Premature Ovarian Insufficiency cost? (2026)
- Premature Ovarian Insufficiency stem cell therapy — your questions answered (2026)
- Premature Ovarian Insufficiency: cell-therapy evidence by therapy class
- MSC vs PRP for Premature Ovarian Insufficiency: what the registries show